NanoSyrinx announces closure of its Pre-Seed investment round

The team at NanoSyrinx are delighted to announce our pre-seed financing with an excellent board of investors: MVentures, BioCity and UKI2S.

Our seed round is helping us deliver key scientific milestones as we look to create a revolution in the delivery of biologic molecules in the cell and gene therapy and conventional therapeutic space.

NanoSyrinx is now preparing for its next full seed raise Q4-2020/Q1-2021, so if you’d like to be involved in the next round and join us on our journey, please get in touch!

Full press release details can be found here:
https://www.sciadnewswire.com/news/604/synthetic-biology-start-nanosyrinx-secures-capital-develop-its-fully-customisable-platform

Follow us on social media to stay up to date!

@NanoSyrinx

https://www.linkedin.com/company/nanosyrinx

Read more news

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines          

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials […]

Read more
Nature Biopharma Dealmakers figure of the NanoSyrinx platform

NanoSyrinx featured in Nature Biopharma Dealmakers

NanoSyrinx is delighted to have been featured in Nature’s Biopharma Dealmakers in an in-depth article exploring how the company is engineering bacterial nanomachines into a new therapeutic modality for targeted intracellular protein delivery. The article highlights NanoSyrinx’s progress in tackling the longstanding challenge that >80% of intracellular targets remain undruggable, our platform’s ability to deliver […]

Read more
Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more
See more news